Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 7, 2007 - Issue 9
Submit an article Journal homepage
74
Views
7
CrossRef citations to date
0
Altmetric
Editorial

The therapeutic potential of targeting anti-Ribosomal-P antibody in treating SLE patients with depression

Miri Blank Tel-Aviv University, The Autoimmune Disease Center, Department of Medicine ‘B’, Sheba Medical Center, Sackler Faculty of Medicine, Israel +972 3 530 2652; +972 3 535 2855; [email protected]
,
Imbal Beinglass Tel-Aviv University, The Autoimmune Disease Center, Department of Medicine ‘B’, Sheba Medical Center, Sackler Faculty of Medicine, Israel +972 3 530 2652; +972 3 535 2855; [email protected]
&
Yehuda Shoenfeld Tel-Aviv University, The Autoimmune Disease Center, Department of Medicine ‘B’, Sheba Medical Center, Sackler Faculty of Medicine, Israel +972 3 530 2652; +972 3 535 2855; [email protected]; Tel-Aviv University, Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Israel
Pages 1283-1285 | Published online: 29 Aug 2007

Bibliography

  • ACR AD HOC COMMITTEE ON NEUROPSYCHIATRY LUPUS NOMENCLATURE: The American college of rheumatology nomenclature and case definitions for neuropsychiatry lupus syndromes. Arthritis Rheum. (1999) 42(4):599-608.
  • GREENWOOD DL, GITLITS VM, ALDERUCCIO F, SENTRY JW, TOH BH: Autoantibodies in neuropsychiatry lupus. Autoimmunity (2002) 35(2):7986.
  • ELKON KB, PARNASSA AP, FOSTER C: Lupus autoantibodies target ribosomal-P proteins. J. Exp. Med. (1985) 162(2):459-471.
  • BONFA E, GOLOMBEK SJ, KAUFMAN LD et al.: Association between lupus psychosis and anti-ribosomal-P protein antibodies. N. Engl. J. Med. (1987) 317(5):265-271.
  • EBER T, CHAPMAN J, SHOENFELD Y: Anti-ribosomal-P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality? Lupus (2005) 14(8):571-575.
  • GABURO N, TIMOIARIA C, BEUNO C, COSSERMELLI W, CONFA E: In-vivo effects of antiribosomal-P-protein antibodies injections into lateral ventricle of the rat-brain. Arthritis Rheum. (1995) 38(S9):864 (Abstract).
  • KATZAV A, SOLODEEV I, BRODSKY O et al.: Induction of autoimmune depression in mice by anti-ribosomal-P antibodies via the limbic system. Arthritis Rheum. (2007) 56(3):938-948.
  • GAIPL US, SHERIFF A, FRANZ S et al.: Inefficient clearance of dying cells and autoreactivity. Curr. Top. Microbiol. Immunol. (2006) 305:161-176.
  • GAUBITZ M, HERRMANN M, SHAHIN M, SCHOTTE H, WILLEKE P, DOMSCHKE W: Cat scratch disease (bartonellosis) mimicking an SLE flare. Lupus (2001) 10(12):883-885.
  • ZHANG W, REICHLIN M: Production and characterization of human monoclonal anti-idiotype to anti-ribosomal-P antibodies. Clin. Immunol. (2005) 114(2):130-136.
  • KAVERI SV, DIETRICH G, HUREZ V, KAZACJLOME MD: Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin. Exp. Immunol. (1991) 86(2):192-198.
  • SHERER Y, SHOENFELD Y: Idiotypic network dysregulation: a common etiopathogenesis of diverse autoimmune diseases. Appl. Biochem. Biotechnol. (2000) 83(1-3):155-162.
  • SHOENFELD Y, RAUOVA L, GILBURD B et al.: Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int. Immunol. (2002) 14(11):1303-1311.
  • BLANK M, ANAFI L, ZANDMAN-GODDARD G et al.: The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int. Immunol. (2007) 19(7):857-865.
  • PAN ZJ, ANDERSON CJ, STAFFORD HA: Anti-idiotypic antibodies prevent the serologic detection of antiribosomal-P autoantibodies in healthy adults. J. Clin. Invest. (1998) 102(1):215-222.
  • MILSTONE AM, MEYERS K, ELIA J: Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature. Clin. Rheumatol. (2005) 24(4):394-397.
  • LOONEY RJ, ANOLIK JH, CAMPBELL D et al.: B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum. (2004) 50(8):2580-2589.
  • SFIKAKIS PP, SOULIOTIS VL, FRAGIADAKI HM, MOUTSOPOULOS KG, BOLETIS JN, THEOFILOPOULUS AN: Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin. Immunol. (2007) 123(1):66-73.
  • TOKUNAGA M, SAITO K, KAWABATA D et al.: Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann. Rheum. Dis. (2007) 66(4):470-475.
  • ALARCON-SEGOVIA D, TUMLIN JA, FURIE RA et al.: LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. (2003) 8(2):442-454.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.